GB8725811D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB8725811D0
GB8725811D0 GB878725811A GB8725811A GB8725811D0 GB 8725811 D0 GB8725811 D0 GB 8725811D0 GB 878725811 A GB878725811 A GB 878725811A GB 8725811 A GB8725811 A GB 8725811A GB 8725811 D0 GB8725811 D0 GB 8725811D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB878725811A
Other versions
GB2197322B (en
GB2197322A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
National Research Development Corp of India
Original Assignee
National Research Development Corp UK
National Research Development Corp of India
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK, National Research Development Corp of India filed Critical National Research Development Corp UK
Publication of GB8725811D0 publication Critical patent/GB8725811D0/en
Publication of GB2197322A publication Critical patent/GB2197322A/en
Application granted granted Critical
Publication of GB2197322B publication Critical patent/GB2197322B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
GB8725811A 1986-11-05 1987-11-04 Antibodies Expired - Fee Related GB2197322B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868626412A GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies

Publications (3)

Publication Number Publication Date
GB8725811D0 true GB8725811D0 (en) 1987-12-09
GB2197322A GB2197322A (en) 1988-05-18
GB2197322B GB2197322B (en) 1990-10-10

Family

ID=10606821

Family Applications (2)

Application Number Title Priority Date Filing Date
GB868626412A Pending GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies
GB8725811A Expired - Fee Related GB2197322B (en) 1986-11-05 1987-11-04 Antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB868626412A Pending GB8626412D0 (en) 1986-11-05 1986-11-05 Antibodies

Country Status (5)

Country Link
EP (1) EP0289546A1 (en)
JP (1) JPH01501200A (en)
AU (1) AU616871B2 (en)
GB (2) GB8626412D0 (en)
WO (1) WO1988003565A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
EP0294703B1 (en) * 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
CA1338518C (en) * 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
EP0334300A1 (en) * 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
FI105320B (en) * 1988-04-04 2000-07-31 Oncogen Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
WO1990006133A1 (en) * 1988-11-25 1990-06-14 Centocor, Inc. Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
WO1991000360A1 (en) * 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE4419399C1 (en) * 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Process for the preparation of heterologous bispecific antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0826696B1 (en) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Use of bi-and trispecific antibodies for inducing tumor immunity
EP0826695B1 (en) 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Destruction of contaminating tumor cells in stem cell transplants by use of bispecific antibodies
CA2457143A1 (en) * 2001-08-17 2003-02-27 Roger Williams Hospital In situ immunization
US7282205B2 (en) 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
ES2528384T3 (en) 2001-12-12 2015-02-09 The Government Of The United States Of America, As Represented By The Secretary Department Of Healt Methods of using adenosine receptor inhibitors to enhance the immune response and inflammation
MXPA05003049A (en) 2002-09-19 2005-11-17 Us Gov Health & Human Serv P. ariasi.
ES2447843T3 (en) 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2432091T5 (en) 2005-03-25 2022-03-18 Gitr Inc GITR binding molecules and uses thereof
ES2547463T3 (en) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses thereof
EP2397852B1 (en) 2006-03-14 2013-12-04 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
EP2444410A3 (en) 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
ES2591281T3 (en) 2007-07-12 2016-11-25 Gitr, Inc. Combination therapies that employ GITR binding molecules
AU2009294850B2 (en) 2008-09-22 2015-07-02 Oregon Health & Science University Methods for detecting a Mycobacterium tuberculosis infection
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
PL2975051T3 (en) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9181306B2 (en) 2009-10-16 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
CN102713629B (en) 2009-11-20 2016-02-24 俄勒冈健康科学大学 For detecting the method for m tuberculosis infection
EP2591006B1 (en) 2010-07-09 2019-04-24 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
RU2608640C2 (en) 2010-08-16 2017-01-23 Новиммун С.А. Methods for generation of multispecific and multivalent antibodies
AU2011295722B2 (en) 2010-09-03 2016-04-21 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
EP2524699A1 (en) 2011-05-17 2012-11-21 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
ES2703780T3 (en) 2011-05-17 2019-03-12 Trion Res Gmbh Preparation of a vaccine containing trifunctional antibodies with potentiating properties of antigen immunogenicity
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
ES2872081T3 (en) 2011-08-05 2021-11-02 Regeneron Pharma Humanized Universal Light Chain Mice
EP2748198A2 (en) 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
PL2802606T3 (en) 2012-01-10 2018-09-28 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
US9566329B2 (en) 2012-04-06 2017-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, attenuated rubella vector to express vaccine antigens
US20150224181A1 (en) 2012-09-14 2015-08-13 The United States Of America As Represented By The Secretary Department Of Health And Human Se Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
CA2881559C (en) 2012-09-24 2020-08-04 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
ES2639559T3 (en) 2012-12-28 2017-10-27 Ventana Medical Systems, Inc. Image analysis for breast cancer prognosis
WO2014164472A1 (en) 2013-03-10 2014-10-09 The Board Of Regents Of The University Of Texas System Biomarkers for chagas disease related cardiomyopathy
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015199976A1 (en) 2014-06-24 2015-12-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Target activated microdissection
AR101262A1 (en) 2014-07-26 2016-12-07 Regeneron Pharma PURIFICATION PLATFORM FOR Bispecific Antibodies
AU2015300915B2 (en) 2014-08-08 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
US11014088B2 (en) 2016-03-09 2021-05-25 The Board Of Regents Of The University Of Texas System Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
AU2018347796A1 (en) 2017-10-10 2020-05-07 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2024044687A1 (en) 2022-08-26 2024-02-29 Valo Health, Inc. Biomarker combinations for prognosis and management of diabetic retinopathy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
ES8504461A1 (en) * 1982-04-12 1985-04-16 Hybritech Inc Antibodies having dual specificities, their preparation and uses therefor.

Also Published As

Publication number Publication date
JPH01501200A (en) 1989-04-27
GB2197322B (en) 1990-10-10
GB2197322A (en) 1988-05-18
WO1988003565A1 (en) 1988-05-19
GB8626412D0 (en) 1986-12-03
AU8156987A (en) 1988-06-01
EP0289546A1 (en) 1988-11-09
AU616871B2 (en) 1991-11-14

Similar Documents

Publication Publication Date Title
GB2197322B (en) Antibodies
GB2209757B (en) Altered antibodies
GB8408193D0 (en) Antibodies
GB2197323B (en) Antibodies
GB8608068D0 (en) Monoclonal antibodies
GB8614084D0 (en) Immunoassay
GB8624899D0 (en) Monoclonal antibodies
GB8621910D0 (en) Monoclonal antibodies
GB8505487D0 (en) Antibodies
GB8715347D0 (en) Monoclonal antibodies
GB8726230D0 (en) Antibodies
GB8616174D0 (en) Monoclonal antibodies
GB8629740D0 (en) Immunoassay
GB8710074D0 (en) Antibodies
GB8610203D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
GB8610318D0 (en) Antibodies
GB8623088D0 (en) Antibodies
GB8620589D0 (en) Antibodies
GB8619998D0 (en) Antibodies
GB8621240D0 (en) Antigens
GB2215725B (en) Monoclonal antibodies
GB8708648D0 (en) Antibodies
GB8729520D0 (en) Antibodies
GB8506372D0 (en) Antibodies

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19931104